GtoPdb Ligand ID: 10694

Synonyms: ALD-403 | ALD403 | eptinezumab-jjmr | Vyepti®
eptinezumab is an approved drug (FDA (2020))
Compound class: Antibody
Comment: Eptinezumab is a humanized IgG1 anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the prevention of migraine [6]. It was developed by Lundbeck and their subsidiary Alder Biopharmaceuticals (Alderbio). The INN record for eptinezumab indicates that it binds to CALCA (α-CGRP) and CALCB (β-CGRP). Peptide sequence alignment using NCBI BLAST Protein reveals 100% matches with sequences claimed in Alderbio's patent WO2012162257A2, and distinguish eptinezumab as the monoclonal referred to as Ab5 in the patent document.

CGRP plays an important role in migraine pathophysiology [2], and both the CGRP peptide and its receptor (CGRPR) are targets of anti-migraine therapeutics [1,4-5]. Eptinezumab is the fourth anti-CGRP pathway monoclonal to reach the clinic: the others are erenumab (anti-CGRPR), galcanezumab (anti-CALCA/B) and fremanezumab (anti-CALCA/B). These antibodies are used as alternatives to CGRPR antagonists such as ubrogepant (FDA approved in 2019).
Compound class Antibody
Approved drug? Yes (FDA (2020))
International Nonproprietary Names
INN number INN
10308 eptinezumab
ALD-403 | ALD403 | eptinezumab-jjmr | Vyepti®
Database Links
Specialist databases
IMGT/mAb-DB 648
Other databases
GtoPdb PubChem SID 404859141
Search PubMed clinical trials eptinezumab
Search PubMed titles eptinezumab
Search PubMed titles/abstracts eptinezumab